Summit Therapeutics (SMMT) Q2 FY26 earnings call

Summit Therapeutics reported Q2 FY26 results highlighted by updated overall survival data for its HARMONi trial, showing consistent benefit across geographies with increased follow-up. The company is advancing its broad ivonescimab clinical development program, including the fully enrolled HARMONi-3 study, and preparing for a potential U.S. FDA approval later this year. Management emphasized the platform potential of ivonescimab across solid tumors and its strong cash position to support ongoing development and commercialization efforts.